Two new drugs equally effective against common skin cancer
Stephen FellerPHOENIX, March 31 (UPI) -- Two drugs, Vismodegib and Sonidegib, were found to be equally effective against basal cell carcinoma, according to researchers. (Source: Health News - UPI.com)
Source: Health News - UPI.com - March 31, 2016 Category: Consumer Health News Source Type: news
Scientists issue report advances in basal cell carcinoma
A new report details how two relatively new drugs are helping patients with basal cell carcinoma. Basal cell carcinoma is the most common type of skin cancer, producing nearly 2.8 million new cases annually in the US, and sunny Arizona has one of the world's highest incidences of skin cancer. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 31, 2016 Category: Science Source Type: news
TGen and Mayo Clinic scientists issue report in Cell on advances in basal cell carcinoma
(The Translational Genomics Research Institute) An article in the journal Cell by top scientists from the Translational Genomics Research Institute (TGen) and Mayo Clinic in Arizona details how two relatively new drugs are helping patients with basal cell carcinoma. Basal cell carcinoma is the most common type of skin cancer, producing nearly 2.8 million new cases annually in the US, and sunny Arizona has one of the world's highest incidences of skin cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 31, 2016 Category: Cancer & Oncology Source Type: news
Head and neck tumours: illustrated
Presentations of head and neck tumours including basal cell carcinoma and squamous cell carcinoma. (Source: GP Online Education)
Source: GP Online Education - March 7, 2016 Category: Primary Care Tags: 12 Care of People with Cancer and Palliative Care Source Type: news
Skin cancer: To each tumor its particularities, to each tumor its treatment
(Université de Genève) 90 percent of the population are at risk to develop a skin cancer, called basal cell carcinoma, one day. Although common, this cancer is rarely fatal and has until now been little studied. But geneticists sequenced the DNA of these skin tumors, in order to determine the genes that are responsible for the cancerogenesis. Their discovery of new cancer genes that cause BCC can pave the way for new treatment methods personalized for each tumor. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 7, 2016 Category: Cancer & Oncology Source Type: news
Anti-TNF therapy linked to ‘modest’ extra SCC risk
A Swedish population-based study shows that treatment with tumour necrosis factor inhibitors significantly increases the risk of developing squamous cell carcinoma, but not basal cell carcinoma, in patients with rheumatoid arthritis. (Source: MedWire News)
Source: MedWire News - February 11, 2016 Category: Consumer Health News Tags: Oncology Source Type: news
Organ transplant recipients face increased risk of BCC
Recipients of a solid organ transplant face up to a sixfold increase in the risk of developing a basal cell carcinoma – a risk that seems to increase as time passes.
A pretransplant history of squamous cell carcinoma (SCC) increased this risk to 55 times that seen in the general population, Dr.... (Source: Skin and Allergy News)
Source: Skin and Allergy News - January 31, 2016 Category: Dermatology Source Type: news
New EMA Advice for PML Prevention With Fingolimod in MSNew EMA Advice for PML Prevention With Fingolimod in MS
The European Medicines Agency recommends evaluating patients for progressive multifocal leukoencephalopathy and for basal cell carcinoma before and during treatment with fingolimod (Gilenya). News Alerts (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - December 19, 2015 Category: Neurology Tags: Neurology & Neurosurgery News Alert Source Type: news
Higher risk of basal cell carcinoma linked to menopausal hormone therapy
Late age of natural menopause and use of menopausal hormone therapy were associated with significantly increased risk of basal cell carcinoma (BCC), according to results of a large, nationwide cohort study.
Women who experienced menopause at age 55 years or later, compared with age 50-54 years,... (Source: Skin and Allergy News)
Source: Skin and Allergy News - November 2, 2015 Category: Dermatology Source Type: news
VivoSight OCT scanner significantly improves early-stage diagnosis of basal cell carcinoma
(Halsin Partners) Recent data shows that the VivoSight OCT scanner significantly improves diagnosis of basal-cell carcinoma at an earlier stage and reduces diagnostic biopsies by 36 percent. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 20, 2015 Category: Cancer & Oncology Source Type: news
Bree Towner has drastic surgery to re-build her face using skin from her scalp
WARNING GRAPHIC CONTENT: Bree Towner, 28, from Illinois, was diagnosed with a skin cancer called basal cell carcinoma. She lost the tip of her nose and now has to shave the new grafted one. (Source: the Mail online | Health)
Source: the Mail online | Health - October 2, 2015 Category: Consumer Health News Source Type: news
Vismodegib, Radiotherapy Promising in Recurrent Advanced BCCVismodegib, Radiotherapy Promising in Recurrent Advanced BCC
Two case might set the stage for the concurrent use of vismodegib and radiotherapy in recurrent advanced basal cell carcinoma (BCC). Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 17, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Sonidegib (Odomzo) Approved for Basal Cell Carcinoma in EUSonidegib (Odomzo) Approved for Basal Cell Carcinoma in EU
The new drug is approved for patients with locally advanced basal cell carcinoma who are not amenable to curative therapy or radiation. News Alerts (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 20, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
Odomzo (sonidegib) for the Treatment of Locally Advanced Basal Cell Carcinoma
Odomzo® (sonidegib) is an oral, selective smoothened (SMO) inhibitor indicated for the treatment of adult patients with locally advanced basal cell carcinoma (laBCC). The drug was discovered and developed by Novartis. (Source: Drug Development Technology)
Source: Drug Development Technology - July 29, 2015 Category: Pharmaceuticals Source Type: news
Medical News Today: FDA approve new daily pill for common skin cancer
The FDA have approved a new drug - sonidegib - for treating locally advanced basal cell carcinoma, an increasingly common cancer that occurs in the top layer of the skin. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 27, 2015 Category: Consumer Health News Tags: Melanoma / Skin Cancer Source Type: news
